SCHEMBL13041807

SCHEMBL13041807

O=C1N/C(=N/c2c(Cl)cccc2Cl)S/C1=C\c1ccc2nccnc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 5/20 1.00
GSK3B P49841 3/20 1.00
CLK1 P49759 2/20 1.00
DYRK1A Q13627 2/20 1.00
DYRK2 Q92630 2/20 1.00
DYRK1B Q9Y463 2/20 1.00
CSNK1E P49674 1/20 1.00
CLK2 P49760 1/20 1.00
CLK3 P49761 1/20 1.00
CLK4 Q9HAZ1 1/20 1.00
DYRK4 Q9NR20 1/20 1.00
PIK3CD O00329 1/20 0.61
NPC1 O15118 1/20 0.61
CSNK2A2 P19784 1/20 0.61
MAOB P27338 1/20 0.61
PIK3CA P42336 1/20 0.61
PIK3CB P42338 1/20 0.61
MTOR P42345 1/20 0.61
PIK3CG P48736 1/20 0.61
RAB9A P51151 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29716638 1.00 DYRK3 (1.00) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL13041788 1.00 DYRK3 (1.00) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL13266165 0.91 DYRK3 (0.84) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL13241248 0.91 DYRK3 (0.84) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL13078147 0.89 DYRK3 (0.80) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL13041813 0.89 DYRK3 (0.80) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL2811101 0.89 DYRK3 (0.80) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL2811103 0.89 DYRK3 (0.80) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL2786265 0.88 DYRK3 (0.80) DYRK3GSK3BCLK1DYRK1ADYRK2
SCHEMBL13078042 0.88 DYRK3 (0.80) DYRK3GSK3BCLK1DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286041-A1 (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE SMITHKLINE BEECHAM CORPORATION 2010-11-11 US disclosed
US-20100286041-A1 (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE SMITHKLINE BEECHAM CORPORATION 2010-11-11 US disclosed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
US-7674792-B2 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-7674792-B2 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells GLAXOSMITHKLINE LLC 2007-08-02 US disclosed
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells GLAXOSMITHKLINE LLC 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286041-A1 (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE HYPK, HIPK3, HIPK1 DYRK3 44/4885GSK3B 842/4885CLK1 175/4885
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells HCLS1, HIPK3, HYPK DYRK3 423/4885GSK3B 1486/4885CLK1 523/4885
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 DYRK3 3748/4885GSK3B 202/4885CLK1 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.